Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2003
10/08/2003CN1447697A Antitumor effect potentiators
10/08/2003CN1447696A Gene detection assay for improving likelihood of effective response to erbb antagonist cancer therapy
10/08/2003CN1447691A Pharmaceutical combination of angiotensin Ôàí antagonists and ace inhibitors
10/08/2003CN1123345C Compsns. of treating ARDS or IRDS
10/08/2003CN1123343C Nicotine compsns. and method for formulation thereof
10/08/2003CN1123342C Use of inhibitors of renin-angiotension system
10/07/2003US6630574 Compositions and methods for the therapy and diagnosis of lung cancer
10/07/2003US6630516 Application of an effective, non-toxic amount of at least one active ingredient that inhibits MMPs and promotes procollagen synthesis; especially a retinoid selected from retinol, retinal, retinoic acid, or a retinoic acid salt
10/07/2003US6630514 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
10/07/2003US6630510 Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections
10/07/2003US6630502 Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
10/07/2003US6630492 Lymphocyte function antigen-1 antagonists
10/07/2003US6630480 Methods of treating leukemia
10/07/2003US6630466 Anticholinergics which have a long-lasting effect, such as glycopyrronium bromide, tiotropium bromide or an ester of bi-or tricyclic amino alcohol such as a nortropanol
10/07/2003US6630458 Teat dipping agent
10/07/2003US6630454 Method and pharmaceutical composition for the treatment of cancer
10/07/2003US6630337 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
10/07/2003US6630313 Phosphatidyl serine receptors and uses thereof
10/07/2003US6630310 Assay for binding between carbohydrate and glycolipid
10/07/2003US6630178 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
10/07/2003US6630173 Mixture with antiproliferative agent
10/07/2003US6630168 Dimethylacetamide in combination with methyl cellulose, hydroxypropyl methylcellulose, or carboxypolymethylene; intralesional administering
10/07/2003US6630163 Method of treating dermatological disorders with fruit extracts
10/07/2003US6630162 Pharmaceutical formulation and its use
10/07/2003US6630155 Thermoplastic base polymer, a solvent, a poly(lactide-co-glycolide)/polyethylene glycol block polymer
10/07/2003US6630154 Polymer formulations containing perfluorinated compounds for the engineering of cells and tissues for transplantation that improves cell metabolism and survival, and methods for making same
10/07/2003US6630138 Protein C derivatives
10/07/2003US6630124 Combination therapy with VIP antagonist
10/07/2003US6630120 Co-administering intravascularly a bradykinin agonist that increases the transport of said substance from the bloodstream to the internal spaces of said non-central nervous system solid tumor
10/07/2003US6629988 Composite staple for completing an anastomosis
10/07/2003CA2280290C Netrin receptors
10/07/2003CA2258146C Synthetic polysaccharides, method for preparing same and pharmaceutical compositions containing said polysaccharides
10/07/2003CA2241288C Pseudoephedrine hydrochloride extended release tablets
10/02/2003WO2003081258A2 Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs)
10/02/2003WO2003081251A1 Novel compositions and methods in cancer associated with altered expression of prdm 11
10/02/2003WO2003081250A1 Novel compositions and methods in cancer associated with altered expression of prlr
10/02/2003WO2003080853A1 Novel compositions and methods in cancer associated with altered expression of tbx21
10/02/2003WO2003080836A1 Nerve regeneration genes
10/02/2003WO2003080813A2 Lactobacillus strains
10/02/2003WO2003080808A2 Novel compositions and methods in cancer
10/02/2003WO2003080794A2 Inhibition of rna function by delivery of inhibitors to animal cells
10/02/2003WO2003080639A1 Novel compositions and methods in cancer associated with altered expression of kcnj9
10/02/2003WO2003080638A2 Antisense iap nucleobase oligomers and uses thereof
10/02/2003WO2003080630A2 Phosphate transport inhibitors
10/02/2003WO2003080629A2 Phosphorus-containing compounds with polymeric chains, and methods of making and using the same
10/02/2003WO2003080582A2 Fredericamycin derivatives
10/02/2003WO2003080557A1 Substituted 4-aminocyclohexanols
10/02/2003WO2003080545A2 Substituted phenylacetic acids
10/02/2003WO2003080183A1 Pharmaceutical combination of the cox-2 inhibitor etodolac and opioids
10/02/2003WO2003080171A1 Intraductal management of breast lesions involving therapeutic or diagnostic agents
10/02/2003WO2003080144A1 Composition for hard tissue augmentation
10/02/2003WO2003080118A2 Combination of an aldosterone receptor antagonist and a fibric acid derivative
10/02/2003WO2003080116A1 Modulating angiogenesis
10/02/2003WO2003080112A2 Imidazoquinolineamines as adjuvants in hiv dna vaccination
10/02/2003WO2003080104A2 Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
10/02/2003WO2003080103A1 Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents
10/02/2003WO2003080083A1 Use of adenoviruses mutated in the va genes for cancer treatment
10/02/2003WO2003080077A1 Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination
10/02/2003WO2003080071A1 Novel therapeutical use of agonist ligands specific to g2a receptor
10/02/2003WO2003080070A2 Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer
10/02/2003WO2003080069A1 Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
10/02/2003WO2003080068A1 Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
10/02/2003WO2003080053A1 Combination treatments for chemokine-mediated diseases
10/02/2003WO2003080049A1 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
10/02/2003WO2003080044A1 Anti-cancer combinations of dmxaa and a nsaid
10/02/2003WO2003080039A1 In vivo use of glutathionone s-transferase activated nitric oxide donors
10/02/2003WO2003080038A1 Preventive or therapeutic agent for kidney disease
10/02/2003WO2003080037A2 Use of ltb4 antagonists in veterinary medicine
10/02/2003WO2003080027A1 Nanoparticulate compositions of angiogenesis inhibitors
10/02/2003WO2003080024A2 Nanoparticulate compositions of map kinase inhibitors
10/02/2003WO2003080022A2 Analgesics for nasal administration
10/02/2003WO2003080021A2 Formulation comprising buprenorphine
10/02/2003WO2003079998A2 Treatment of diseases involving defective gap junctional communication
10/02/2003WO2003079987A2 A non-selective cation channel in neural cells and methods for treating brain swelling
10/02/2003WO2003079981A2 Bioadhesive drug delivery system
10/02/2003WO2003079978A2 Protease activity of thrombin inhibits angiogenesis
10/02/2003WO2003079973A2 Mitotic kinesin inhibitors
10/02/2003WO2003079972A2 Active agent delivery systems and methods for protecting and administering active agents
10/02/2003WO2003079969A2 Compositions and methods for treating and preventing necrosis
10/02/2003WO2003079923A1 Method of administering an injectable antibiotic to the ear of an animal
10/02/2003WO2003079885A2 Inhalable sustained therapeutic formulations
10/02/2003WO2003070177A3 Use of melatonin analogues for induction of general anesthesia
10/02/2003WO2003061638A3 Use of phosphodiesterase antagonists to treat insulin resistance
10/02/2003WO2003061577A3 Polyalkylene glycol with moiety for conjugating biologically active compound
10/02/2003WO2003053358A3 Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
10/02/2003WO2003051370A8 Selective dopamine d3 receptor agonists for the treatment of sexual dysfunction
10/02/2003WO2003046180A3 Human cdnas and proteins and uses thereof
10/02/2003WO2003043669A8 Composition and method for treatment of wounds
10/02/2003WO2003042173A8 Nk1 antagonists
10/02/2003WO2003020206A3 Use of atazanavir in hiv therapy
10/02/2003WO2003011906A3 Use of peptide fragments of the calcium channel α-1 subunit, optionally comprising mutations, for screening molecules of therapeutic interest
10/02/2003WO2003009779A3 Delivery of therapeutic capable agents
10/02/2003WO2003002107A3 Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
10/02/2003WO2002099056A3 C22c7orfs as modifiers of the p53 pathway and methods of use
10/02/2003WO2002092759A3 Molecules for disease detection and treatment
10/02/2003WO2002085405A3 COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
10/02/2003WO2002074323A3 Using neural thread proteins to treat tumors and other hyperproliferative disorders
10/02/2003WO2002070737A9 Compositions and methods relating to osteoarthritis
10/02/2003WO2002069944A3 Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists
10/02/2003WO2002066016A3 Mucoadhesive dispersible pharmaceutical preparation for active-agent dosing in veterinary and human medicine
1 ... 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 ... 1151